Fortress Biotech (FBIO) Stock: Buy, Sell, or Hold?
FBIO - Fortress Biotech, Inc.
$2.52
-0.05 (-1.95%)
▼
5d:
-7.01%
30d:
-8.36%
90d:
-8.7%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When FBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: FBIO shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: FBIO shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: FBIO is currently trading at $2.52, which is considered oversold relative to its 30-day fair value range of $2.65 to $2.87. From a valuation perspective, the stock is trading at a discount (Forward PE: -2.5) compared to its historical average (136.2). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, FBIO is in a uptrend. The price is currently testing key support at $2.52. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: FBIO scores 24/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.00 (+336.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, FBIO is in a uptrend. The price is currently testing key support at $2.52. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: FBIO scores 24/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.00 (+336.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.65 -
$2.87
Company Quality Score
40/100
(SELL)
Options IV Signal
53th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
63.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 53th percentile)
- BEARISH: Weak technical setup (24/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 336.5% below Wall St target ($11.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.65 -
$2.87
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.39
(15.5%)
Support & Resistance Levels
Support Level
$2.52
Resistance Level
$2.81
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.52
Wall Street Target
$11.00
(+336.5%)
Revenue Growth (YoY)
14.0%
Profit Margin
163.3%
PE vs Historical
-2.5 vs 136.2
CHEAP
Share & Embed Analysis
Last updated: September 13, 2026 10:42 AM ET
Data refreshes hourly during market hours. Next update: 11:42 AM
Data refreshes hourly during market hours. Next update: 11:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FBIO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$21 | 48 HOLD |
